Purpose In RTOG0114 trial, 2-year disease-free survival (DFS) of taxol-based regimen failed to exceed lower bound of 52.9% and can t be recommended for future trial.We analyze 2 year results to evaluate postoperative concurrent chemoradiation of capecitabine combined with intensity-modulated radiotherapy (IMRT) in gastric cancer.Method Analysis were performed in stageⅡ/Ⅲ (AJCC 7th) gastric cancer patients who underwent macroscopically radical(R0/R1) gastric surgery and postoperative concurrent chemoradiation of capcitabine combined with IMRT.Whole group were admitted with average 4 cycles fluorouracil-based chemotherapy and concurrent chemoradiation of IMRT (45Gy/25f) combined with capecitabine (1,600 mg/m2 / day for 5 weeks), those who underwent R1 resection were admitted with extra boost of 5-10Gy to pathologically positive margin.Two-years DFS 52%was lower bound for phase Ⅱ study.Toxicities of whole group were graded according CTC-AE(v3.0).Result Until 2011, altogether 43 were evaluable , including 12 stage Ⅱ and 31 stage Ⅲ patients.With a median follow-up of 21months, 2-year DFS and OS is 55.6% and 82.3% for the whole group, respectively.Patients who underwent R0 resection (n=35) versus R1 resection (n=8) showed improvement in 2-year DFS in R0 (70.4% v 18.8%; P =0.001), but no significant difference in 2-year OS (86.3% v 70.0%; P =0.176).Patients who underwent D1 versus D2 dissection demonstrated no significant difference.Acute toxicities(≥grade 3) of global, GI and hematology were 27.9%, 13.9% and 9.3%, respectively.Conclusion Capecitabine combined with IMRT can be recommended as adjuvant treatment for resected gastric cancer in our future tri